癌变·畸变·突变2025，Vol.37Issue(4)：310-313,318,5.DOI:10.3969/j.issn.1004-616x.2025.04.014
血清Lipocalin-2和YKL-40联合检测对食管癌患者新辅助放化疗效果的预测价值
Relationships between serum Lipocalin-2 and YKL-40 levels on therapeutic effect of neoadjuvant radiotherapy and chemotherapy in esophageal cancer patients
摘要
Abstract
OBJECTIVE:To investigate the levels of Lipocalin-2 and YKL-40 in serum samples from esophageal cancer(EC)patients and their relationship with therapeutic effect of neoadjuvant radiotherapy and chemotherapy.METHODS:From January 2021 to August 2022,a total of 200 EC patients who underwent neoadjuvant radiotherapy and chemotherapy in the Hankuang General Hospital of North China Medical and Health Group were recruited as research subjects.All patients were examined 5 cycles after treatment,according to the therapeutic effect of patients.They were grouped into effective(128 cases)and ineffective groups(72 cases).The contents of serum Lipocalin-2,YKL-40 and carcinoembryonic antigen(CEA)were compared between the two groups before treatment;logistic regression was applied to analyze the influencing factors of neoadjuvant radiotherapy and chemotherapy therapeutic effect in EC patients.Receiver operating characteristic(ROC)was applied to analyze the predictive value of serum Lipocalin-2,YKL-40 and CEA in the therapeutic effect among the patients.RESULTS:Compared with the effective group,the contents of serum Lipocalin-2,YKL-40,and CEA in the ineffective group were significantly increased(P<0.05).Serum Lipocalin-2,YKL-40,and CEA were the factors for the therapeutic effect of the two therapies(P<0.05).ROC curve showed that the AUC of combined serum Lipocalin-2,YKL-40 and CEA predicted the efficacy of the therapy at 0.975,with sensitivity of 95.65%,and specificity of 89.29%.It was better than the three individual predictions(Zcombination-Lipocalin-2=23.868,P<0.01;Zcombination-YKL-40=3.918,P<0.01;Zcombination-CEA=3.742,P<0.01).CONCLUSION:Serum Lipocalin-2 and YKL-40 contents were significantly increased in patients who did not respond to EC neoadjuvant chemoradiotherapy,and the combination of Lipocalin-2 and YKL-40 with the traditional tumor marker CEA has good reference value in predicting the therapeutic effect of neoadjuvant radiotherapy and chemotherapy for EC.关键词
脂质运载蛋白/壳多糖酶3样蛋白1/食管癌/新辅助放化疗/疗效Key words
lipocalin/chitosanase 3-like protein 1/esophageal cancer/neoadjuvant radiotherapy and chemotherapy/therapeutic effect分类
医药卫生引用本文复制引用
杨智慧,韩翔龙,刘艮钢,石捷..血清Lipocalin-2和YKL-40联合检测对食管癌患者新辅助放化疗效果的预测价值[J].癌变·畸变·突变,2025,37(4):310-313,318,5.基金项目
河北省中医药管理局资助项目(2020601) （2020601）
